{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:46:21Z","timestamp":1769597181520,"version":"3.49.0"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Despite major therapeutic improvements, children with relapsed\/refractory Acute Myeloid Leukaemia still have poor outcomes and overall survival does not exceed 40%. New treatments are required to improve their outcome; Gemtuzumab ozogamicin (GO), an anti\u2010CD33 immunoconjugate antibody, is a potent cytotoxic agent whose efficacy has been demonstrated mainly in adults. The main objective of this retrospective multicentre study was to assess the outcome of children treated, between February 2008 and August 2019, with GO at a single 4.5\u00a0mg\/m<jats:sup>2<\/jats:sup> dose, in combination with Fludarabine, Cytarabine and antssshracyclines, in context of a first relapse (<jats:italic>n<\/jats:italic>\u00a0=\u00a026) or refractory disease (<jats:italic>n<\/jats:italic>\u00a0=\u00a03). The remission rate was 83% (24\/29 children) and 20 children (69%) were allografted. With a median follow\u2010up of 1.2\u2009years (range: 0.1\u20138), the overall survival was 49% (CI95%\u00a0=\u00a033; 72). Most common adverse event was febrile neutropenia with microbiological identification in 55% of cases. Veno\u2010occlusive disease occurred in 6 patients (21%), of which 5 subvened after bone marrow transplantation, and resolved within 2\u201332\u2009days (median 10.5\u2009days). Administration of GO in combination with FLA\u2010anthracyclines chemotherapy appears to be a good reinduction regimen for relapsed or refractory AML with a good safety profile. These results warrant larger prospective study.<\/jats:p>","DOI":"10.1111\/bjh.18203","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T11:38:46Z","timestamp":1650368326000},"page":"373-381","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Single\u2010dose (4.5\u00a0mg\/m<sup>2<\/sup>) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia"],"prefix":"10.1111","volume":"198","author":[{"given":"Chlo\u00e9","family":"Dhunputh","sequence":"first","affiliation":[{"name":"Paediatric Haematology Oncology Unit, CHU de Bordeaux Universit\u00e9 de Bordeaux  Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Strullu","sequence":"additional","affiliation":[{"name":"Paediatric Haematology Unit AP\u2010HP, Hopital Robert D\u00e9br\u00e9, APHP  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8363-1622","authenticated-orcid":false,"given":"Arnaud","family":"Petit","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Centre de Recherche Saint\u2010Antoine UMR_S938 Paediatric Haematology Oncology Unit, AP\u2010HP, Armand Trousseau Hospital  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Merched","sequence":"additional","affiliation":[{"name":"CIC P\u00e9diatrique 1401 CHU Bordeaux  France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marl\u00e8ne","family":"Pasquet","sequence":"additional","affiliation":[{"name":"Paediatric Haematology Oncology Unit CHU de Toulouse  France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saba","family":"Azarnoush","sequence":"additional","affiliation":[{"name":"Paediatric Haematology Unit AP\u2010HP, Hopital Robert D\u00e9br\u00e9, APHP  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Leverger","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Centre de Recherche Saint\u2010Antoine UMR_S938 Paediatric Haematology Oncology Unit, AP\u2010HP, Armand Trousseau Hospital  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-0838","authenticated-orcid":false,"given":"St\u00e9phane","family":"Ducassou","sequence":"additional","affiliation":[{"name":"Paediatric Haematology Oncology Unit, CHU de Bordeaux Universit\u00e9 de Bordeaux  Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0071-7"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.18.18"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102336"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2021.1841640"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.01.025"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06326.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2017.10.008"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404434"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60485-1"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188888"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.7384"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-1947"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3821"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07370.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.191841"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.4310"},{"issue":"1","key":"e_1_2_6_18_1","first-page":"e31","article-title":"Molecular profiling defines distinct prognostic subgroups in childhood AML: a report from the French ELAM02 study group","volume":"2","author":"Marceau\u2010Renaut A","year":"2018","journal-title":"Hema"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000159"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.181.181"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28736"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28305"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25057"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403350"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.6846"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.066"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.187153"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401141"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29341"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2016.1129903"},{"issue":"10","key":"e_1_2_6_31_1","first-page":"1396","article-title":"A prospective survey on incidence, risk factors and therapy of hepatic veno\u2010occlusive disease in children after hematopoietic stem cell transplantation","volume":"90","author":"Cesaro S","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.024"},{"key":"e_1_2_6_33_1","article-title":"Risk assessment for hepatic veno\u2010occlusive disease inpatients treated with gemtuzumab ozogamicin(Mylotarg) with or without hematopoietic stem cell transplantation [abstract]","volume":"102","author":"Erba HP","year":"2003","journal-title":"Blood"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaa076"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00313"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18203","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.18203","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T22:59:07Z","timestamp":1692831547000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1111\/bjh.18203"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18203","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]},"assertion":[{"value":"2022-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}